Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

20.71 +0.71 (+3.55%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,010,644
Open 20.25
Bid (Size) 19.01 (100)
Ask (Size) 21.50 (1,500)
Prev. Close 20.00
Today's Range 19.91 - 21.38
52wk Range 3.420 - 30.00
Shares Outstanding 36,130,121
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
From UroGen Pharma Ltd.
Via GlobeNewswire

Performance

YTD
-8.8%
-8.8%
1 Month
-6.4%
-6.4%
3 Month
+4.5%
+4.5%
6 Month
-0.0%
-0.0%
1 Year
+84.7%
+84.7%

More News

Read More
News headline image
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally ↗
Via The Motley Fool
Topics Death Regulatory Compliance
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen (URGN) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
UROGEN PHARMA LTD (NASDAQ:URGN) Reports Q3 2025 Earnings: Revenue Misses, Loss Per Share Beats ↗
Via Chartmill
News headline image
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Present at Upcoming Investor Conferences
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen (URGN) Q2 Revenue Rises 11% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
UROGEN PHARMA LTD (NASDAQ:URGN) Reports Mixed Q2 2025 Earnings Amid Widening Losses and Revenue Beat ↗
Via Chartmill
News headline image
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025
From UroGen Pharma Ltd.
Via GlobeNewswire
News headline image
UROGEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors in to Inquire About Their Rights in Class Action Lawsuit
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology
From UroGen Pharma Ltd.
Via GlobeNewswire

Frequently Asked Questions

Is UroGen Pharma Ltd. - Ordinary Shares publicly traded?
Yes, UroGen Pharma Ltd. - Ordinary Shares is publicly traded.
What exchange does UroGen Pharma Ltd. - Ordinary Shares trade on?
UroGen Pharma Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for UroGen Pharma Ltd. - Ordinary Shares?
The ticker symbol for UroGen Pharma Ltd. - Ordinary Shares is URGN on the Nasdaq Stock Market
What is the current price of UroGen Pharma Ltd. - Ordinary Shares?
The current price of UroGen Pharma Ltd. - Ordinary Shares is 20.71
When was UroGen Pharma Ltd. - Ordinary Shares last traded?
The last trade of UroGen Pharma Ltd. - Ordinary Shares was at 02/04/26 04:00 PM ET
What is the market capitalization of UroGen Pharma Ltd. - Ordinary Shares?
The market capitalization of UroGen Pharma Ltd. - Ordinary Shares is 748.25M
How many shares of UroGen Pharma Ltd. - Ordinary Shares are outstanding?
UroGen Pharma Ltd. - Ordinary Shares has 748M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.